MedTrace Logo

Study of DE-089 Ophthalmic Solution in Patients With Dry Eye

NCT01101984 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2012-11-14

No results posted yet for this study

Summary

Safety and efficacy of DE-089 ophthalmic solution in patients with dry eye will be evaluated in comparison with sodium hyaluronate ophthalmic solution.

Conditions

  • Dry Eye

Interventions

DRUG

diquafosol ophthalmic solution

DE-089 topical ocular application, 6 times daily for 4 weeks.

DRUG

0.1% sodium hyaluronate ophthalmic solution.

0.1% HA topical ocular application, 6 times daily for 4 weeks.

Sponsors & Collaborators

  • Santen Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
69 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-02-28
Completion
2012-04-30

Countries

  • China
  • Singapore

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01101984 on ClinicalTrials.gov